Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 12;9(1):72.
doi: 10.1186/s13195-017-0300-8.

Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume

Affiliations

Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume

Jessica Z K Caldwell et al. Alzheimers Res Ther. .

Abstract

Background: Alzheimer's disease (AD) impacts men and women differently, but the effect of sex on predementia stages is unclear. The objective of this study was to examine whether sex moderates the impact of florbetapir positron emission tomography (PET) amyloid positivity (A+) on verbal learning and memory performance and hippocampal volume (HV) in normal cognition (NC) and early mild cognitive impairment (eMCI).

Methods: Seven hundred forty-two participants with NC and participants with eMCI from the Alzheimer's Disease Neuroimaging Initiative (second cohort [ADNI2] and Grand Opportunity Cohort [ADNI-GO]) were included. All had baseline florbetapir PET measured, and 526 had screening visit HV measured. Regression moderation models were used to examine whether A+ effects on Rey Auditory Verbal Learning Test learning and delayed recall and right and left HV (adjusted for total intracranial volume) were moderated by diagnosis and sex. Age, cognition at screening, education, and apolipoprotein E ε4 carrier status were controlled.

Results: Women with A+, but not those with florbetapir PET amyloid negative (A-),eMCI showed poorer learning. For women with NC, there was no relationship of A+ with learning. In contrast, A+ men trended toward poorer learning regardless of diagnosis. A similar trend was found for verbal delayed recall: Women with A+, but not A-, eMCI trended toward reduced delayed recall; no effects were observed for women with NC or for men. Hippocampal analyses indicated that women with A+, but not those with A-, eMCI, trended toward smaller right HV; no significant A+ effects were observed for women with NC. Men showed similar, though nonsignificant, patterns of smaller right HV in A+ eMCI, but not in men with A- eMCI or NC. No interactive effects of sex were noted for left HV.

Conclusions: Women with NC showed verbal learning and memory scores robust to A+, and women with A+ eMCI lost this advantage. In contrast, A+ impacted men's scores less significantly or not at all, and comparably across those with NC and eMCI. Sex marginally moderated the relationship of A+ and diagnosis with right HV, such that women with NC showed no A+ effect and women with A+ eMCI lost that advantage in neural integrity; the pattern in men was less clear. These findings show that women with A+ eMCI (i.e., prodromal AD) have differential neural and cognitive decline, which has implications for considering sex in early detection of AD and development of therapeutics.

Keywords: Alzheimer’s disease; Amyloid; Memory; Mild cognitive impairment (MCI); PET; Volumetric magnetic resonance imaging (MRI).

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

All data included in this article were collected for research use as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. ADNI is a longitudinal, multisite AD biomarker study (www.adni-info.org) that offers de-identified data meeting criteria for limited datasets to qualified researchers with scientific or educational institution affiliations, upon review. Ethics approval for data collection in ADNI was obtained by each ADNI participating institution’s institutional review board. All participants gave written informed consent at participating institutions. The authors of this paper were granted approved access to the ADNI data, and the ADNI Data Sharing and Publications Committee (DPC) approved this paper for submission to Alzheimer’s Research and Therapy (date of approval, February 24, 2017).

Consent for publication

Not applicable.

Competing interests

JZKC, JLB, and SJB declare that they have no competing interests. JLC declares having received in kind research support from Avid Radiopharmaceuticals, Teva Pharmaceuticals, and CogState; having done consultation for AbbVie, ACADIA Pharmaceuticals, Accera, Actinogen Medical, Adamas Pharmaceuticals, Alkahest, Alzheon, Anavex Life Sciences, Astellas Pharma, AstraZeneca, Avanir Pharmaceuticals, Axovant Sciences, Biogen Idec, Biotie Therapies, Boehinger Ingelheim, Chase Pharmaceuticals, Eisai, FORUM Pharmaceuticals, Genentech, Grifols, Intra-Cellular Therapies, Iris Pharma, Ionis Pharmaceuticals, Eli Lilly and Company, Lundbeck, Merck, Neurotrope BioScience, Novartis, Nutricia, Otsuka, Pfizer, Probiodrug, QR Pharma, Resverlogix, Roche, Servier, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Taisho Toyama Pharmaceutical Co., Transition Therapeutics, United Neuroscience, GE Healthcare, and MedAvante; owning stock in Adamas Pharmaceuticals, Prana Biotechnology, Sonexa Therapeutics, MedAvante, NeuroTrax, and Neurokos; and owning the copyright of the Neuropsychiatric Inventory. In addition, JLC has provided expert witness/legal consultation regarding olanzapine and ropinerole.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Sex moderation of diagnosis and amyloid status effects. Sex moderates effects of diagnosis and florbetapir positron emission tomography amyloid positivity (A+) on verbal learning (a) and marginally moderates effects on verbal delayed recall (b) and right hippocampal volume (HV; d), but it does not moderate effects on left HV (c). Specifically, learning and memory scores appear robust to A+ effects in women with normal cognition (NC; a, b). Women with prodromal AD (A+ early mild cognitive impairment [eMCI]) lose this advantage (a, b). In contrast, A+ impacts men’s verbal learning and memory scores comparably across NC and eMCI (a, b). Sex shows no moderating effect for left HV (c), but individuals of both sexes with eMCI show smaller left HV than individuals with NC. Sex marginally moderates the relationship of A+ and diagnosis with right HV, such that women with NC showed no effect of A+ on HV and women with prodromal AD lost that advantage in neural integrity (d). A Florbetapir positron emission tomography amyloid negativity, AVLT Auditory Verbal Learning Test. Rey AVLT scores are group means. HV units are derived via correction for total intracranial volume

References

    1. Jack CR, Jr, Barrio JR, Kepe V. Cerebral amyloid PET imaging in Alzheimer’s disease. Acta Neuropathol. 2013;126:643–57. doi: 10.1007/s00401-013-1185-7. - DOI - PMC - PubMed
    1. Ewers M, Insel P, Jagust WJ, Shaw L, Aisen P, Petersen RC, et al. CSF biomarker and PIB-PET-derived β-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012;22:1993–2004. doi: 10.1093/cercor/bhr271. - DOI - PMC - PubMed
    1. Yau WY, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2015;14:804–13. doi: 10.1016/S1474-4422(15)00135-0. - DOI - PMC - PubMed
    1. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86. doi: 10.1002/ana.23650. - DOI - PMC - PubMed
    1. Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, et al. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology. 2015;85:790–8. doi: 10.1212/WNL.0000000000001903. - DOI - PMC - PubMed